Left atrial appendage occlusion (LAAO) with the WATCHMAN FLX (Boston Scientific) has been proven to reduce stroke risk in patients with paroxysmal atrial fibrillation (PAF). Certain circumstances may ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

Regulatory approvals and trials, particularly for WATCHMAN FLX Pro and FARAPULSE, are crucial for future performance and could introduce short-term volatility. Given the rich valuation and ...

REDDING, Calif. — The staff at Shasta Regional Medical Center (SRMC) is celebrating their 100th Watchman heart implant ...

TCT 537: Optimization of Access Using Dedicated RF-TSP Devices Increases Efficiency and Consistency of LAAC With WATCHMAN FLX Pro: A Report From HEAL-LAA Primary Analysis Subset Receive the the latest ...

Strong worldwide demand for its Electrophysiology and Structural Heart lines, traction in United States and outside for its the next generation WATCHMAN FLX and FLX Pro, as well as contribution ...

Wednesday, October 30, 2024 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including ...

It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that ...

波士顿科学公司(NYSE: NYSE:BSX)在最新的财报电话会议上详细介绍了其心脏病学业务的最新情况。高级副总裁Jon Monson和包括执行副总裁Joe Fitzgerald在内的领导团队讨论了公司在心脏病学市场的战略性增长。该市场价值近400亿美元,预计到2027年复合年增长率将达到8%。 公司报告称,今年迄今为止美国市场增长率为27%,国际市场增长率为18%,这主要得益于ICTx和EP业务 ...